Management tracks: Atara names Novartis’ Touchon as CEO; plus Intellia, Arch Oncology
Atara Biotherapeutics Inc. (NASDAQ:ATRA) hired Pascal Touchon as president and CEO, effective June 24. He was global head cell & gene at Novartis AG (NYSE:NVS; SIX:NOVN), where he was responsible for the global launch of Kymriah tisagenlecleucel. Former President and CEO Isaac Ciechanover had announced his intention to step down from the allogeneic T cell immunotherapy company in January. The company also said Dietmar Berger, global head of R&D, has resigned to pursue other opportunities.
CRISPR gene editing company Intellia Therapeutics Inc. (NASDAQ:NTLA) hired Laura Sepp-Lorenzino as EVP and CSO. She succeeds former CSO Tom Barnes, who transitioned to chief innovation officer in October 2017. Sepp-Lorenzino was VP, head of nucleic acid therapies, external innovation at Vertex Pharmaceuticals Inc. (NASDAQ:VRTX)...